Skip to main content

Table 2 Therapeutic and microbiological details according to the type of treatment

From: Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case–control study

Variable Number (%) of patients p value
DC group (n = 48) ST group (n = 96)
Polymicrobial infection 6 (12.5) 17 (17.7) 0.57
 CR Acinetobacter baumannii 3 (6.25) 12 (12.5) 0.4
 CR Pseudomonas aeruginosa 3 (6.25) 5 (5.2) 0.89
Combined targeted therapy 35 (72.9) 52 (54.2) 0.05
 DC + colistin 19 (39.6)
 DC + gentamicin 8 (16.9)
 DC + tigecycline 3 (6.25)
 DC + colistin + tigecycline 2 (4.2)
 DC + colistin + gentamicin 3 (6.25)
 Colistin + tigecycline 22 (22.9)
 Colistin + gentamicin 13 (13.5)
 Gentamicin + tigecycline 10 (10.4)
 Colistin + tigecycline + gentamicin 7 (7.3)
Extensively drug-resistant strainsa 32 (66.7) 31 (32.3) <0.01
 Colistin MIC ≤ 2 μg/ml 28 (58.3) 64 (66.7) 0.42
 Gentamicin MIC ≤ 2 μg/ml 15 (31.3) 72 (75) <0.01
 Tigecycline MIC ≤ 1 μg/mlb 16 (47.1) 58 (60.4) 0.27
 Suboptimal MIC valuesc 10 (20.8) 14 (14.6) 0.5
  1. Bold data are significant
  2. DC double carbapenem, ST standard treatment, CR carbapenem resistant, MIC minimal inhibitory concentration
  3. aStrains resistant to at least one agent in all but two or fewer usually active antimicrobial categories
  4. bMIC values were available in 130 patients: 34 pts (DC group) and 96 patients (ST group)
  5. cGentamicin (4 μg/ml), tigecycline (2 μg/ml)